Chris Daige
Mirna Therapeutics (United States)(US)
Publications by Year
Research Areas
Cholesterol and Lipid Metabolism, MicroRNA in disease regulation, Peroxisome Proliferator-Activated Receptors, Cancer, Lipids, and Metabolism, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → Identification of macrophage liver X receptors as inhibitors of atherosclerosis(2002)436 cited
- → Macrophage Liver X Receptor Is Required for Antiatherogenic Activity of LXR Agonists(2004)281 cited
- → Promoter-Specific Roles for Liver X Receptor/Corepressor Complexes in the Regulation of ABCA1 and SREBP1 Gene Expression(2003)233 cited
- → Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)(2009)161 cited
- → Non-redundant roles for LXR and LXR in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice(2010)94 cited
- → Non-redundant roles for LXRα and LXRβ in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice(2009)26 cited
- → MRX34, a liposomal miR-34 mimic and potential first-in-class microRNA therapeutic: activity in animal models of liver cancer.(2016)5 cited
- → Abstract C142: The development of a miRNA-based therapeutic candidate for hepatocellular carcinoma.(2011)4 cited
- → Abstract LB-250: Development of a miR34-based cancer therapy.(2013)
- → Abstract B57: miR-34 mimics synergize with small molecule inhibitors targeting the EGFR and Raf kinase pathways(2015)